# Nuclide record pylarify (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/pylarify/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "pylarify" ;
  schema:name "Piflufolastat F-18 / Pylarify TruVu"@en ;
  schema:description "Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026."@en ;
  schema:url <https://nuclide.cc/drugs/pylarify/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Piflufolastat_F-18> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Piflufolastat%20F-18> ;
  nuclide:status "approved" ;
  nuclide:modality "PET imaging agent" ;
  schema:alternateName "Pylarify" ;
  nuclide:approval "US 2021: PSMA PET imaging in prostate cancer", "US 2026: Pylarify TruVu formulation", "EU 2023: EU brand Pylclari (Curium)" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/lantheus/> .